717843-48-6

Basic information

• Product Name: 3-Bromo-2-cyano-6-methylpyridine
• Synonyms: 3-Bromo-2-cyano-6-methylpyridine;3-Bromo-6-methylpicolinon...;2-Cyano-3-Methyl-5-broMopyridine;3-Bromo-6-methylpicolinonitrile, 3-Bromo-2-cyano-6-methylpyridine;3-Bromo-6-methyl pyridine-2-nitrile;3-Bromo-6-methyl-2-pyridinecarbonitrile
• CAS NO: 717843-48-6
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.032
• EINECS: -0
• Mol File: 717843-48-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 299.304 °C at 760 mmHg
• Flash Point: 134.815 °C
• Appearance: /
• Density: 1.613 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -1.95±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-2-cyano-6-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-2-cyano-6-methylpyridine(717843-48-6)
• EPA Substance Registry System: 3-Bromo-2-cyano-6-methylpyridine(717843-48-6)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 717843-48-6(Hazardous Substances Data)

Usage

General Description

3-Bromo-2-cyano-6-methylpyridine is a chemical compound with the molecular formula C7H5BrN2. It presents as a yellow to brown crystalline solid and is known for its application in the pharmaceutical industry as a key intermediate in the synthesis of various pharmaceutical drugs. 3-Bromo-2-cyano-6-methylpyridine is used in the production of active pharmaceutical ingredients and is also utilized in the manufacturing of agrochemicals. Additionally, 3-Bromo-2-cyano-6-methylpyridine serves as a building block in the creation of various organic chemicals and is commonly employed in research and development laboratories for its versatile chemical properties. Furthermore, it is crucial to handle and store this chemical compound with appropriate safety measures and in a controlled environment to prevent any potential hazards.

InChI:InChI=1/C7H5BrN2/c1-5-2-3-6(8)7(4-9)10-5/h2-3H,1H3

Upstream product

• 3430-13-5 5-bromo-2-methylpyridine 
• 7677-24-9 trimethylsilyl cyanide 
• 31181-64-3 5-bromo-2-methyl-pyridine-N-oxide 

Downstream Products

• 1268817-70-4 2-(2-{[(2S,5S)-2-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)-5-methyl-1-piperidinyl]carbonyl}-6-methyl-3-pyridinyl)pyrimidine 
• 1620-75-3 2-Cyano-6-methylpyridine 
• 1384199-29-4 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinonitrile 
• 1384199-28-3 6-methyl-3-(1H-1,2,3-triazol-1-yl)-2-pyridinecarbonitrile 
• 1252905-76-2 (1R,4S,6R)-4-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)-3-{[6-methyl-3-(2-pyrimidinyl)-2-pyridinyl]carbonyl}-3-azabicyclo[4.1.0]heptane 
• 779344-30-8 3-bromo-6-methyl-2-pyridinecarboxylic acid 
• 1060810-14-1 3-bromo-6-methyl-2-pyridinecarboxaldehyde 

Relevant articles and documents

IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF

The present disclosure provides compounds represented by Formula (I) wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula (I) are FED inhibitors. FED inhibitors are useful for the treatment of cancer and other diseases.

FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF

The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

Method for totally synthesizing natural product (+/-)-rupestine G and resolving enantiomers

The invention relates to a method for totally synthesizing a natural product (+/-)-rupestine G and resolving enantiomers. The method comprises the following steps: oxidizing the raw material 2-methyl-5-bromopyridine (1) by m-chloroperoxybenzoic acid to obtain a nitrogen oxidation product compound 2, carrying out a Reissert-Henze reaction to perform cyano substitution so as to obtain a compound 3, carrying out a decarboxylation reaction on the compound 3 and potassium monoethyl malonate to obtain beta-ketoester 4, carrying out alkylation under the condition of sodium ethylate to obtain a compound 5, carrying out a coupling reaction to obtain a compound 6, carrying out an intramolecular olefin double replacement reaction on the compound 6 to obtain a key intermediate compound 7, carrying out reduction with sodium borohydride to obtain a compound 8, carrying out a reaction under the condition of pyridine/MsCl to obtain a compound 9, hydrolyzing the compound 9 under the action of lithium hydroxide, carrying out methyl esterification by using iodomethane to obtain a compound 10, carrying out palladium-carbon catalytic hydrogenation to obtain a pair of diastereoisomers 11 and 12, and carrying out resolution by a semi-preparative high performance liquid chromatograph to obtain the natural product rupestine G and three stereoisomers, namely a compound 13, a compound 14 and a compound 15.